TGFB1 and neoplasm: A novel study proposed that membrane-anchored, tumor-targeted IL-12 T cells (attIL12-T) trigger IFNγ release by binding to CSV, inhibit TGF-β signaling, upregulate FAS expression on CAFs, and activate the caspase-3/PARP apoptosis pathway.